Page 857 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 835

Prednisolone, dose and effects of Proportional morbidity/mortality, 82t Pulmonary lymphomatoid granulomatosis
(PLG), 690–691
for cats, 293t–294t Proportional mortality rate Pulmonary mass, CT of, 118f
for dogs, 292t
statistics on, 83–84
VetBooks.ir Prednisone, 196 PROs. see Patient-reported outcomes Pulmonary neoplasia, 507
true mortality rate versus, 83–84, 84f
dose and effects of
clinical signs of, 507–508
for cats, 293t–294t Prospective cohort study, 86 comparative aspects of, 513–514
for dogs, 292t Prostaglandin synthase, 308f diagnostics for, 508–510
Preputial tumor Prostaglandins, tumor-associated, 100 clinical laboratory findings in, 508
canine, 636–637 Prostate computed tomography for, 509–510,
feline, 637 cell characteristics in, 634f 509f
Preservation, of biopsy sample, 61–62 transitional cell carcinoma cells and, 134f fine-needle aspiration in, 510
Pretreatment biopsy, 158 Prostate cancer near-infrared (NIR) imaging for, 510
indications for, 158 incidence of, 19 preterm-biopsy for, 510
Prevalence, 82t pain caused by, 287t thoracic radiographs in, 508–509,
Prevention, for feline sarcoma, 424–425 sex hormones and, 92 508f–509f
Primary aldosteronism, 573 testosterone and, 19 ultrasound for, 509
Primary bone tumors Prostate carcinoma incidence of, 507
of cats, 553–555 breed predilections for, 632 natural behavior of, 507
diagnostic workup for, 554 metastasis of, 633 pathology of, 507
history and clinical signs in, 554 risk factors for, 631 physical examination for, 507–508
incidence and risk for, 553–554 types of, 631 prognosis of, 513–514
pathology and natural behavior in, 554 Prostate gland tumor, 134 risk factors for, 507
therapy and prognosis of, 554–555 Prostatectomy, 634 treatment for, 511–513
of dogs, 550 Prostatic artery embolization (PAE), 178 chemotherapy in, 511–512
Primary hyperaldosteronism, 573 Prostatic carcinoma, 634f interventional therapy in, 512–513
Primary hyperparathyroidism, 580–581 Prostatic intraepithelial neoplasia (PIN), 631 radiation therapy in, 512
Primary ocular tumors, 678–684 Prostatic mineralization surgery in, 511, 512f
canine anterior uveal melanomas, 678–679 neoplasia and, 633 Pulmonary/lung carcinoma, 68t
choroidal melanomas, 680 radiograph of, 633f Punch biopsy, 159–160
feline ocular posttraumatic sarcoma, Proteasome, 270–271, 270t mechanisms of, 160f
681–682, 681f 26S Proteasome, 270 Purdue University Veterinary Teaching
feline primary intraocular melanomas Proteasome inhibition Hospital, 651–652
(feline diffuse iris melanoma), chemicals for, 271 Purina body condition scoring system, 303f
680–681, 680f molecular targets and consequences of, 271t
iridociliary epithelial tumors, 682 tumor cells and, 270–271 Q
orbit and optic nerve tumors, 683–684 Protein Quadratic component, 214
secondary uveal neoplasms, 682–683 nutritional benefit of, 307–308 Quality of life, assessment for, 317
spindle cell tumors (uveal schwannoma), production of, 270 Quick Romanowsky stain, 128–129
682 Protein kinase Quiescence, 5
Primary osteosarcoma, in axial skeleton, 524 classification of, 257–258
Primer synthesis, 148 dysfunction of, 259–260 R
Primitive follicular epithelium tumor, dysregulation mechanisms for, 259–260 Radiation
355–356 role of, 42 observational studies for cancer from,
Proangiogenic factor, 264 in signal transduction, 257–258 87t–91t
Procarbazine, 192 types of, 42t as physical carcinogen, 16
Prodrug cancer gene therapy, 256 Proteolysis, 301 Radiation atypical fibroblast, 65
activating gene delivery and, 255f Proto-oncogene, 526 Radiation carcinogenesis, 16
mesenchymal stem cells and, 256 activation of, 1 factors influencing, 212
Progesterone, 18 cell growth/proliferation and roles of, 41 Radiation dose
Progestin, 604–605 conversion of, 42 absorbed energy and, 211
Progestin-induced growth hormone, 18 role of, 4–5, 25 dividing into fractions, importance of,
Prognosis, discussing, 316–317 Prussian blue stain, 129 211–212
Programmed death-1/programmed death Pseudocapsule, 167 surviving fraction of cells and, 214
ligand-1 (PD-1/PD-L1), 231 PTCL-NOS. see Peripheral T-cell lymphoma- Radiation oncology, 209–230
Progression model, 55 not otherwise specified acronyms commonly used in, 210t
Progression-free rate (PFR), 342–343 PTV. see Planning target volume Radiation therapy (RT), 113, 209, 212f
Progression-free survival (PFS), 342–343, 368 Pulmonary adenocarcinoma, 135 for adrenal medullary tumors, 573–574
Proliferating cell nuclear antigen (PCNA), Pulmonary carcinoma for bladder tumors, 649
385–386 cells from, 130f bone tumors assessment, 114f
Prophase, 36 fine-needle aspiration of, 130f for canine osteosarcoma, 541–542
Proportional measure, 83–84 Pulmonary Langerhans cell histiocytosis, for canine pituitary-dependent
Proportional morbidity ratio (PMR), 83 792t, 797 hypercortisolism, 568